Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 4Neoplasms 3Sarcoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Adenocarcinoma of Lung 2Stomach Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Glioma 1EGFR-mutant Non-small Cell Lung Cancer 1Carcinoma 1Bronchial Neoplasms 1

Interventions

Carboplatin 3selpercatinib 2pembrolizumab 2durvalumab 2Radiosurgery 2Pemetrexed 2Cisplatin 2sotorasib 1repotrectinib 1ceralasertib 1cemiplimab 1capmatinib 1aflutinib 1Toll-Like Receptor 1 1Platinum Compounds 1Paclitaxel 1Gemcitabine 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchial Neoplasms × capmatinib × 1 year × Clear all
NCT05110196 2026-04-07

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Novartis

Phase 4 Completed
50 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡